Cadrenal Therapeutics Inc (CVKD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.22-4.69%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CVKD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CVKD — earnings miss
Dated 2026-08-13
and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this
Why it matters: Updates on fund use can show financial health and good management.
Watch forA clear plan for using funds that makes investors feel secure.
Also watch forMore share dilution or bad terms in new warrant deals.
Why it matters: A new CEO can change the direction of the company. This could affect future growth and investor confidence.
Watch forThe company announces a clear strategic plan or vision under the new CEO within three months.
Also watch forThere is no new plan. Operations are not changing.
Why it matters: Stable leadership helps manage losses and improves cash flow.
Worry ifA new permanent CEO or CMO is announced to stabilize leadership.
Less concerning ifMore leaders are leaving. There are no new hires or temporary leaders.
Why it matters: If the healthcare sector's revenue growth picks up, it could benefit Cadrenal and its peers.
Supportive ifHealthcare sector revenue growth is speeding up again. It is close to 10% year over year.
Worry ifHealthcare sector revenue growth is slowing down. It is now below 5% year over year.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$375 on $10,000 · ±3.7% | How much price usually moves either way. |
| Bad day | $888 loss on $10,000 · 8.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,141 loss on $10,000 · 91.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Worsening cash flow shows bigger financial problems. This can hurt future funding and operations.
Worry ifCash flow from operations worsens to below -$3,500,000 in Q2.
Less concerning ifCash flow from operations improves to above -$2,500,000 in Q2.
Why it matters: Advancing to Phase 3 is crucial for CAD-1005's potential market entry. Positive trial results could attract partnerships and funding.
Supportive ifManagement starts the Phase 3 trial for CAD-1005.
Worry ifManagement delays or cancels the Phase 3 trial for CAD-1005.
Why it matters: Partnerships can give money and help to move Cadrenal's late-stage assets forward.
Supportive ifA partnership or licensing deal for CAD-1005, frunexian, or tecarfarin is made.
Worry ifIf no partnerships are announced by Q3 2026, it shows trouble in making deals.
Why it matters: FDA guidance will clarify the path for CAD-1005 to treat HIT. Positive feedback may boost confidence in the trial's success.
Supportive ifOfficial FDA meeting minutes confirm a clear path for the Phase 3 trial of CAD-1005.
Worry ifFDA raises concerns about the trial design or endpoints, delaying progress.
Why it matters: Getting a partnership could bring funding and help CAD-1005's development. This would improve its market chances.
Supportive ifThere is news about a partnership or licensing deal for CAD-1005.
Worry ifThere are no news about partnerships or talks for CAD-1005.